Immediate Impact
72 standout
Citing Papers
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
Works of Anna L. Emanuel being referenced
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
2019 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Anna L. Emanuel | 47 | 28 | 67 | 220 | 150 | 9 | 376 | |
| Jaap A. Joles | 51 | 7 | 84 | 171 | 89 | 10 | 411 | |
| Lasse Bent-Hansen | 64 | 15 | 112 | 151 | 61 | 15 | 382 | |
| Rodolfo Nasti | 42 | 57 | 126 | 113 | 100 | 13 | 417 | |
| D. Kremer | 31 | 15 | 172 | 151 | 94 | 18 | 418 | |
| Natalie Mordi | 34 | 8 | 139 | 188 | 96 | 6 | 399 | |
| Romeo García-Torres | 71 | 7 | 82 | 141 | 87 | 9 | 449 | |
| Livia Giannini | 42 | 9 | 159 | 283 | 124 | 10 | 416 | |
| Kushwin Rajamani | 46 | 9 | 96 | 178 | 159 | 10 | 403 | |
| Hardik Vasnawala | 30 | 10 | 92 | 149 | 133 | 12 | 376 | |
| Sharon L. Reilly | 58 | 7 | 71 | 195 | 163 | 12 | 449 |
All Works
Login with ORCID to disown or claim papers
Loading papers...